|
|
|
08.04.26 - 13:06
|
Glaukos to Release First Quarter 2026 Financial Results after Market Close on April 29 (Business Wire)
|
|
|
Conference Call and Webcast Scheduled for 1:30 p.m. PTALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, plans to release first quarter 2026 financial results after the market close on Wednesday, April 29, 2026. The company's management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on April 29, 2026.
A link to the live webcast will be available on the company's website at http://investors.glaukos.com. To participate in the conference call, please dial 800-715-9871 (U.S.) or 646-307-1963 (International) and enter Conference ID 1333241. A replay will be archived on the company's website following completion of the call.
About Glaukos
Glaukos (www.glaukos.com) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel ...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
17.02.26 - 22:09
|
Glaukos Announces Fourth Quarter and Full Year 2025 Financial Results (Business Wire)
|
|
|
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial results for the fourth quarter and full year ended December 31, 2025. Key highlights include:
Record net sales of $143.1 million in Q4 2025 increased 36% year-over-year on a reported basis and 34% year-over-year on a constant currency basis.
Glaucoma record net sales of $119.2 million in Q4 2025 increased 42% year-over-year.
U.S. Glaucoma record net sales of $86.4 million in Q4 2025 increased 53% year-over-year.
Net sales of $507.4 million in 2025 increased 32% year-over-year.
Reaffirmed 2026 net sales guidance of $600 million to $620 million.
“Our record fourth quarter results cap off a highly successful year of global execution across our key commercial and development initiatives, leaving us well positioned to sustain our strong growth momentum in ...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
